Top

Published in:

01-07-2015 | Nuclear Medicine

Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase ¹⁸ F-FDG PET/CT

Authors: Byung Hyun Byun, Sung Hoon Kim, Sang Moo Lim, Ilhan Lim, Chang-Bae Kong, Won Seok Song, Wan Hyeong Cho, Dae-Geun Jeon, Soo-Yong Lee, Jae-Soo Koh, Soo Kyo Chung

Published in: European Radiology | Issue 7/2015

Abstract

Objectives

We evaluated the ability of dual-phase ¹⁸ F-FDG PET/CT to predict the histological response after neoadjuvant chemotherapy (NAC) in osteosarcoma.

Methods

Thirty-one patients with osteosarcoma treated with NAC and surgery were prospectively enrolled. After injection of ¹⁸ F-FDG, both early (~60 min) and delayed (~150 min) PET were acquired before and after the completion of NAC. SUVmax, early/delayed SUVmax change (RImax), and early/delayed SUVmean change (RImean) of tumour were measured before (SUV1, RImax1, and RImean1) and after NAC (SUV2, RImax2, and RImean2). Then, we calculated the percentage changes between SUV1 and SUV2 (%SUV).

Results

Twelve patients (39 %) exhibited good histological response after NAC. SUVmax, RImax, and RImean significantly decreased after NAC. Before NAC, only RImean1 predicted good histological response with the optimal criterion of < 10 %, sensitivity of 92 %, specificity of 57 %, and accuracy of 71 %. After NAC, %SUV, SUV2, and RImax2 predicted histological response. By using combined criterion of %SUV and RImax2 or SUV2 and RImean1 or SUV2 and RImax2, accuracies were 81 %, 77 %, and 77 %, respectively.

Conclusions

The histological response after NAC could be predicted by using RImean1 before the initiation of NAC in osteosarcoma. The combined use of SUV and RI values may provide a better prediction.

Key Points

• Pretreatment dual-phase FDG-PET was useful to predict histological response in osteosarcoma.

• A combination of early and delayed PET may increase the predictive value.

• Early/delayed SUV change of tumours significantly decreased after neoadjuvant chemotherapy.

Ottaviani G, Jaffe N (2009) The epidemiology of osteosarcoma. Cancer Treat Res 152:3–13PubMed

Collins M, Wilhelm M, Conyers R et al (2013) Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: Findings from a meta-analysis. J Clin Oncol 31:2303–2312PubMedCrossRef

Bacci G, Ferrari S, Bertoni F et al (2000) Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: An updated report. J Clin Oncol 18:4016–4027PubMed

Jeon DG, Song WS (2010) How can survival be improved in localized osteosarcoma? Expert Rev Anticancer Ther 10:1313–1325PubMedCrossRef

Wellings RM, Davies AM, Pynsent PB, Carter SR, Grimer RJ (1994) The value of computed tomographic measurements in osteosarcoma as a predictor of response to adjuvant chemotherapy. Clin Radiol 49:19–23PubMedCrossRef

Kim MS, Lee SY, Cho WH et al (2009) Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response. J Orthop Sci 14:292–297PubMedCrossRef

Cheon GJ, Kim MS, Lee JA et al (2009) Prediction model of chemotherapy response in osteosarcoma by 18 F-FDG PET and MRI. J Nucl Med 50:1435–1440PubMedCrossRef

Byun BH, Kong CB, Lim I et al (2013) Combination of 18 F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: Preliminary results in osteosarcoma. J Nucl Med 54:1053–1059PubMedCrossRef

Byun BH, Kong CB, Lim I et al (2014) Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential F-FDG PET/CT and MRI. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-014-2746-2

10.

Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790PubMedCrossRef

11.

Yoon HJ, Kim SK, Kim TS et al (2013) New application of dual point 18 F-FDG PET/CT in the evaluation of neoadjuvant chemoradiation response of locally advanced rectal cancer. Clin Nucl Med 38:7–12PubMedCrossRef

12.

Chen HH, Lee BF, Su WC et al (2013) The increment in standardized uptake value determined using dual-phase 18 F-FDG PET is a promising prognostic factor in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 40:1478–1485PubMedCrossRef

13.

Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA (1999) A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 26:22–30PubMedCrossRef

14.

Lee S, Park T, Park S et al (2014) The clinical role of dual-time-point (18)F-FDG PET/CT in differential diagnosis of the thyroid incidentaloma. Nucl Med Mol Imaging 48:121–129PubMedCentralPubMedCrossRef

15.

Abgral R, Le Roux PY, Rousset J et al (2013) Prognostic value of dual-time-point 18 F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma. Nucl Med Commun 34:551–556PubMedCrossRef

16.

Houseni M, Chamroonrat W, Zhuang J, Gopal R, Alavi A, Zhuang H (2010) Prognostic implication of dual-phase PET in adenocarcinoma of the lung. J Nucl Med 51:535–542PubMedCrossRef

17.

Lyshchik A, Higashi T, Nakamoto Y et al (2005) Dual-phase 18 F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 32:389–397PubMedCrossRef

18.

Damron TA, Ward WG, Stewart A (2007) Osteosarcoma, chondrosarcoma, and ewing's sarcoma: National cancer data base report. Clin Orthop Relat Res 459:40–47PubMedCrossRef

19.

Rosen G, Marcove RC, Huvos AG et al (1983) Primary osteogenic sarcoma: Eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 106(Suppl):55–67PubMedCrossRef

20.

Coffin CM, Lowichik A, Zhou H (2005) Treatment effects in pediatric soft tissue and bone tumors: Practical considerations for the pathologist. Am J Clin Pathol 123:75–90PubMedCrossRef

21.

Chan YH (2003) Biostatistics 104: Correlational analysis. Singapore Med J 44:614–619PubMed

22.

Denecke T, Hundsdorfer P, Misch D et al (2010) Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging 37:1842–1853PubMedCrossRef

23.

Hawkins DS, Rajendran JG, Conrad EU 3rd, Bruckner JD, Eary JF (2002) Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer 94:3277–3284PubMedCrossRef

24.

Bajpai J, Gamnagatti S, Kumar R et al (2011) Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: Correlation with histological necrosis. Pediatr Radiol 41:441–450PubMedCrossRef

25.

Higashi T, Saga T, Nakamoto Y et al (2002) Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 43:173–180PubMed

26.

Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25:4777–4786PubMedCentralPubMedCrossRef

27.

Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V (2004) In self-defence: Hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J 377:347–355PubMedCentralPubMedCrossRef

28.

Suh DH, Kim MA, Kim H et al (2013) Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer. Clin Exp Med

29.

Ahn KJ, Hwang HS, Park JH et al (2009) Evaluation of the role of hexokinase type II in cellular proliferation and apoptosis using human hepatocellular carcinoma cell lines. J Nucl Med 50:1525–1532PubMedCrossRef

30.

Uesaka D, Demura Y, Ishizaki T et al (2008) Evaluation of dual-time-point 18 F-FDG PET for staging in patients with lung cancer. J Nucl Med 49:1606–1612PubMedCrossRef

31.

Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150SPubMedCentralPubMedCrossRef

32.

Lodge MA, Chaudhry MA, Wahl RL (2012) Noise considerations for PET quantification using maximum and peak standardized uptake value. J Nucl Med 53:1041–1047PubMedCentralPubMedCrossRef

33.

Kawada K, Nakamoto Y, Kawada M et al (2012) Relationship between 18 F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. Clin Cancer Res 18:1696–1703PubMedCrossRef

34.

Smith TA, Appleyard MV, Sharp S, Fleming IN, Murray K, Thompson AM (2013) Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased hexokinase II, glut1 and [18 F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters. Cancer Chemother Pharmacol 71:473–480PubMedCrossRef

Title: Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase 18 F-FDG PET/CT
Authors: Byung Hyun Byun
Sung Hoon Kim
Sang Moo Lim
Ilhan Lim
Chang-Bae Kong
Won Seok Song
Wan Hyeong Cho
Dae-Geun Jeon
Soo-Yong Lee
Jae-Soo Koh
Soo Kyo Chung
Publication date: 01-07-2015
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 7/2015
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-015-3609-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase ¹⁸ F-FDG PET/CT

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Please log in to get access to this content

Other articles of this Issue 7/2015

Whole-body intravoxel incoherent motion imaging

Ultrasound-Based Risk Stratification for Malignancy in Thyroid Nodules: A Four-Tier Categorization System

Adipose tissue compartments, muscle mass, muscle fat infiltration, and coronary calcium in institutionalized frail nonagenarians

Optimal follow-up intervals in active surveillance of renal masses in patients with von Hippel-Lindau disease

Rapid needle-out patient-rollover approach after cone beam CT-guided lung biopsy: effect on pneumothorax rate in 1,191 consecutive patients

Very low mammographic breast density predicts poorer outcome in patients with invasive breast cancer